TOPLINE:

Addition of fotagliptin to metformin significantly reduced A1c levels in patients with type 2 diabetes (T2D) compared with placebo plus metformin without increasing the incidence of hypoglycemic events.

METHODOLOGY:

Previous research indicated that fotagliptin, a dipeptidyl peptidase 4 inhibitor, provided superior glycemic control than placebo in patients with T2D.

Researchers conducted a randomized controlled trial across 53 outpatient clinics in China to evaluate the efficacy and safety of fotagliptin as an add-on to metformin in patients with T2D.

They included 402 patients with T2D (mean age, 55.1 years; mean A1c level, 8.09%; 59% men) who underwent dietary and exercise interventions and received a stable dose of ≥ 1500 mg/d metformin for at least 8 weeks before screening

See Full Page